Search research articles
Contact Us
Filters
Showing results (131-140 of 164) with videos related to
Page
of 17
Sort By:
Blood
|
September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza, James A Reeves, Eric J Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes
Peter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 13, 2006
Myelodysplastic syndromes clinical practice guidelines in oncology
Peter L Greenberg, Maria R Baer, John M Bennett, et al.
Leukemia & Lymphoma
|
February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997
David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Genes, Chromosomes & Cancer
|
September 11, 2015
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group
Friederike Braulke, Catharina Müller-Thomas, Katharina Götze, et al.
Archives of Pathology & Laboratory Medicine
|
March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Savanah D Gisriel, Fnu Aakash, John M Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2012
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge
Julie Schanz, Heinz Tüchler, Francesc Solé, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncology
Peter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 18, 2008
Myelodysplastic syndromes
Peter L Greenberg, Eyal Attar, Minoo Battiwalla, et al.
Page
of 17
Search research articles
Search
Showing results (131-140 of 164) with videos related to
Sort By:
Page
of 17
Blood
|
September 26, 2007
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
Azra Raza, James A Reeves, Eric J Feldman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2003
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
Bruce D Cheson, John M Bennett, Kenneth J Kopecky, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 15, 2011
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes
Peter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
January 13, 2006
Myelodysplastic syndromes clinical practice guidelines in oncology
Peter L Greenberg, Maria R Baer, John M Bennett, et al.
Leukemia & Lymphoma
|
February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997
David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Genes, Chromosomes & Cancer
|
September 11, 2015
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group
Friederike Braulke, Catharina Müller-Thomas, Katharina Götze, et al.
Archives of Pathology & Laboratory Medicine
|
March 9, 2025
Standardization of Bone Marrow Reporting for Myelodysplastic Syndromes/Neoplasms on Behalf of the International Consortium for Myelodysplastic Syndromes/Neoplasms
Savanah D Gisriel, Fnu Aakash, John M Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 15, 2012
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge
Julie Schanz, Heinz Tüchler, Francesc Solé, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
July 13, 2013
Myelodysplastic syndromes: clinical practice guidelines in oncology
Peter L Greenberg, Eyal Attar, John M Bennett, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
October 18, 2008
Myelodysplastic syndromes
Peter L Greenberg, Eyal Attar, Minoo Battiwalla, et al.
Page
of 17